Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain
- 1 December 2000
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 36 (18) , 2344-2352
- https://doi.org/10.1016/s0959-8049(00)00304-x
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- An estimate of the annual direct cost of treating cutaneous melanomaJournal of the American Academy of Dermatology, 1998
- A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanomaEuropean Journal Of Cancer, 1997
- Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.Journal of Clinical Oncology, 1997
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Guidelines for authors and peer reviewers of economic submissions to the BMJBMJ, 1996
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Economic Analysis of Health Technologies and ProgrammesPharmacoEconomics, 1995
- The annual risk of melanoma progression. Implications for the concept of cureCancer, 1992
- Late Recurrence of Malignant MelanomaAnnals of Surgery, 1990
- A comparative cost analysis of terminal cancer care in home hospice patients and controlsJournal of Chronic Diseases, 1987